Botulinum toxin – mechanism of action and experience with treatment in primary headaches
Keywords:
primary headache, botulinum toxin, prophylaxis, onabotulinumtoxin A, mechanism, preventionAbstract
Onabotulinumtoxin A has been studied in numerous trials as a novel preventive therapy for migraine headache. Consecutive trials have proven its efficacy not only in chronic migraine, but also in episodic migraine, medication overuse and chronic tension type headache. The data suggest that it may be effective at reducing headache days in patients suffering from chronic migraine. The mechanism by which onabotulinumtoxinA exerts its effects on migraine is not yet understood.
It is known to inhibit acetylcholine release at the neuromuscular junction, but this probably does not explain the observed antinociceptive properties noted in preclinical and clinical trials. This review discusses the known mechanisms of action of botulinum toxin type A, and reviews some of the available randomized, placebo-controlled trials that have looked at its efficacy as a preventative. The injected form and excellent tolerability of onabotulinumtoxin A makes it an extremely attractive alternative for chronic migraine patients who have demonstrated poor tolerance or poor compliance with traditional oral prophylactics. There are no clinical trials studying the efficacy of the toxin in primary headaches in Bulgaria.
The most probable reason is the high cost and the variable data from different trials. We need more research data on long-term use of botulinum toxin A in headache patients.
References
Albanese, A. Terminology for preparations of botulinum neurotoxins: what a difference a name makes. Jama, 2011, 305, 1, 89–90.
Antonаcci, F., Rossi, C., Gianfranceschi, L., et al. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci, 2008, 28, 14, 3689–3696.
Aoki, K.R. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology, 2005, 26, 5, 785–793.
Arezzo, J.C. Possible mechanisms for the effects of botulinum toxin on pain. Clin J Pain, 2002, 18, 6 suppl, S125–S132.
Aurora, S.K., Dodick, D.W., Turkel, C.C., et al. onabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia, 2010, 30, 7, 793–803.
Aurora, S.K., Gawel, M., Brandes, J.L., et al. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, doubleblind, placebo- controlled exploratory study. Headache, 2007, 47, 4, 486–499.
Bach-Rojecky, L., Salkovic-Petrisic, M., Lackovic, Z. Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection. Eur J Pharma col, 2010, 633, 1–3, 10–14.
Binder, W.J., Brin, M.F., Blitzer, A. Botulinum toxin type A (BoToX) for treatment of migraine. Semin Cutan Med Surg, 2001,20, 2, 93–100.
Binder, W.J., Brin, M.F., Blitzer, A., et al. Botulinum toxin type A (BoToX) for treatment of migraine headaches: an open-label study. otolaryngol Head Neck Surg, 2000, 123, 6, 669–676.
Blumenfeld, A.M., Schim, J.D., Chippendale, T.J. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache, 2008, 48, 2, 210–220.
Blumenfeld, A.М., Silberstein, S.D., Dodick, D.W., et al. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache, 2010, 50, 9, 1406–1418.
Brin, M.F. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl, 1997, 6, S146–S168.
Brin, M.F., Fahn, S., Moskowitz, C., et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. AdvNeurol, 1988, 50, 599–608.
Cady, R., Schreiber, C. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Headache, 2008, 48, 6, 900–913.
Cady, R.K., Schreiber, C.P., Porter, J.A., et al. A multi-center double- blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache, 2011, 51, 1, 21–32.
Caleo, M., Antonucci, F., Restani, L., Mazzocchio, R. A reappraisal of the central effects of botulinum neurotoxin type A: by what mechanism? J Neurochem., 2009, 109, 1, 15–24.
Diener, H.C., Dodick, D.W., Aurora, S.K., et al. onabotulinumtoxinA for treatment of chronic migraine: results from the doubleblind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia, 2010, 30, 7, 804–814.
Dodick, D.W., Turkel, C.C., Degryse. R.E., et al. onabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache, 2010, 50, 6, 92–136.
Dolly, J.o., Lawrence, G.W., Meng, J., et al. Neuro-exocytosis: botulinumtoxins as inhibitory probes and versatile therapeutics. Curr opin Pharmacol, 2009, 9, 3, 326–335.
Elkind, A.H., o’Carroll, P., Blumenfeld, A., et al. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain, 2006, 7, 10, 688–696.
Evers, S., Rahmann, A., Vollmer-Haase, J. & Husstedt, I-W. Treatment of headache with botulinum toxin A—a review according to evidence-based medicine criteria. Cephalalgia, 2002, 22, 699–710.
Evers, S., Vollmer-Haase, J., Schwaag, S., Rahmann, A., Husstedt, I-W & Frese, A. Botulinum toxin A in the prophylactic treatment of migraine – a randomized, double-blind, placebo-controlled study. Cephalalgia, 2004, 24, 838–843.
Favre-Guilmard, C., Auguet, M., Chabrier, P.E. Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models. Eur J Pharmacol, 2009, 617, 1–3, 48–53.
Foran, P.G., Mohammed, N., Lisk, G.o., et al. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem, 2003, 278, 2, 1363–1371.
Freund, B.J., Schwartz, M. The use of botulinum toxin-A in the treatment of refractory cluster headache: case reports. Cephalalgia, 2000, 20, 329–30.
Frevert, J., Dressler, D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics, 2010, 4, 325–332.
Garza, I., Schwedt, T.J. Chronic migraine. UpToDate, Wolters Kluwer Health, 2011.
Gerwin, R. Treatment of chronic migraine headache with onabotulinumtoxinA. Curr Pain Headache Rep. 2011;15(5):336–338.
Go Іbel, H., Heinze, A., Heinze-Kuhn, K. Botulinum toxin A in the treatment of chronic paroxysmal hemicrania—a case report. Cephalalgia, 2001, 21, 506.
Kitamura, Y., Matsuka, Y., Spigelman, I., et al. Botulinum toxin type a (150 kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction. Neuroscience, 2009, 159, 4, 1422–1429.
Magalhaes, E., Menezes, C., Cardeal, M., Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. Clin Neurol Neurosurg, 2010, 112, 6, 463–466.
Matak, I., Bach-Rojecky, L., Filipovic, B., Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience, 2011, 186, 201–207.
Mathew, N.T., Jaffri, S.F. A double-blind comparison of onabotulinumtoxina (BoToX) and topiramate (ToPAMAX) for the prophylactic treatment of chronic migraine: a pilot study. Headache, 2009, 49, 10, 1466–1478.
Mense, S. Neurobiological basis for the use of botulinum toxin in pain therapy. J Neurol., 2004, 251, 1–I7.
Meunier, F.A., Schiavo, G., Molgo, J. Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J Physiol Paris. 2002, 96, 1–2, 105–113.
Pavone, F., Luvisetto, S. Botulinum neurotoxin for pain management: insights from animal models. Toxins, 2010, 2, 2890–2913.
Rahimtoola, H., Buurma, H., Tijssen, C.C., et al. Migraine prophylactic medication usage patterns in The Netherlands. Cephalalgia, 2003, 23, 4, 293–301.
Relja, M., Poole, A.C., Schoenen, J. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia, 2007, 27, 492–503.
Robbins, L. Botulinum toxin A (Botox) for cluster headache: 6 cases. Cephalalgia, 2000, 21, 499–500.
Robertson, C.E., Garza, I. Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine. Neuropsychiatr Dis Treat, 2012, 8, 35-48.
Rosales, R.L., Bigalke, H., Dressler, D. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol, 2006, 13 suppl , 1, 2–10.
Sampaio, C., Costa, J., Ferreira, J.J. Clinical comparability of marketed formulations of botulinum toxin. Mov Disord, 2004, 19 suppl, 8, S129–S136.
Sandrini, G., Perrotta, A., Tassorelli, C.Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. J Headache Pain, 2011, 12, 4, 427-33.
Saper, J.R., Mathew, N.T., Loder, E.W., et al. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine. Pain Med, 2007, 8, 6, 478–485.
Schulte-Mattler, W.J., Krack, P., BoNTTH Study Group. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain, 2004, 109, 1–2, 110–114.
Silberstein, S.D. Treatment recommendations for migraine. Nat Clin Pract Neurol, 2008, 4, 9, 482–489.
Silberstein, S.D., Gobel, H., Jensen, R. et al. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebocontrolled, parallel- group study. Cephalalgia, 2006, 26, 79–800.
Wey, J.J., Tang, S.S., Wu, T.Y. Disulfide bond reduction corresponds to dimerization and hydrophobi-city changes of Clostridium botulinum type A neurotoxin. Acta Pharmacol Sin, 2006, 27, 9, 1238–1246.
Woodcock, J. Response to citizen petition on botulinum toxin (Docket No. FDA-2008-P-0061). In: FDA, ed 2009.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2014 Veselina Grozeva, B. Popiavanova, V. Todorov, I. Milanov

This work is licensed under a Creative Commons Attribution 4.0 International License.